Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Sold by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC lowered its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 97.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 41,610 shares of the company's stock after selling 1,581,273 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned approximately 0.06% of Phathom Pharmaceuticals worth $338,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new stake in shares of Phathom Pharmaceuticals during the fourth quarter valued at $74,000. Teacher Retirement System of Texas acquired a new stake in shares of Phathom Pharmaceuticals during the 4th quarter worth about $90,000. Versor Investments LP purchased a new stake in shares of Phathom Pharmaceuticals during the fourth quarter worth about $101,000. Virtu Financial LLC acquired a new position in shares of Phathom Pharmaceuticals in the fourth quarter valued at approximately $109,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Phathom Pharmaceuticals during the fourth quarter valued at approximately $125,000. Institutional investors and hedge funds own 99.01% of the company's stock.

Phathom Pharmaceuticals Trading Down 17.9 %

NASDAQ:PHAT traded down $0.60 on Friday, hitting $2.76. 4,676,435 shares of the stock were exchanged, compared to its average volume of 1,066,073. The stock has a market cap of $192.23 million, a PE ratio of -0.49 and a beta of 0.35. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $2.71 and a fifty-two week high of $19.71. The stock has a fifty day moving average of $4.96 and a 200-day moving average of $7.76.

Analysts Set New Price Targets

Several analysts have commented on PHAT shares. Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, February 25th. Craig Hallum reiterated a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Guggenheim decreased their price target on Phathom Pharmaceuticals from $18.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday. The Goldman Sachs Group dropped their price objective on shares of Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday. Finally, HC Wainwright decreased their target price on shares of Phathom Pharmaceuticals from $28.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Phathom Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $18.67.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.